Last reviewed · How we verify
Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy: A Randomized, Parallel, Prospectively-Controlled Outpatient Comparison
To determine, in a randomized, parallel open-label fashion, compliance rates between once-daily extended-release divalproex sodium tablets (Depakote-ER®, Abbott Labs) versus multiple-daily dose valproic acid capsules (Depakene®, Abbott Labs) in an epilepsy population.
Details
| Lead sponsor | Orlando Health, Inc. |
|---|---|
| Status | COMPLETED |
| Enrolment | 5 |
| Start date | 2006-07 |
| Completion | 2007-05 |
Conditions
- Epilepsy
Interventions
- Compliance
Countries
United States